G
Gan & Lee Pharmaceutical
Gan & Lee pharmaceutical is a Chinese high-tech biopharmaceutical company engaged in the R&D of insulin glargine and insulin lispro
About Gan & Lee Pharmaceutical
Gan Lee Pharmaceuticals, headquartered in Beijing, is a leading Chinese pharmaceutical company specializing in the development, production, and commercialization of insulin analogs and medical devices. Founded in 1998, Gan Lee has grown to employ over 4,000 people globally and operates an industrial park spanning approximately 200,000 square meters. The company is renowned for developing the first Chinese domestic insulin analog and has a series of insulin products approved in China. Gan Lee's market extends internationally, with its products available in countries such as Egypt, Pakistan, and Mexico. The company has also established subsidiaries in New Jersey, USA, and Hong Kong, China, to bolster its global business development and production capabilities. Gan Lee serves a diverse clientele, including healthcare providers and patients requiring insulin therapy. The company operates within the biopharmaceutical market, focusing on innovative solutions for diabetes management. Gan Lee's business model revolves around research and development, manufacturing, and sales of its pharmaceutical products, generating revenue through both domestic and international markets. The company's commitment to innovation and quality has earned it numerous accolades, including the 2021 Outstanding Industrial Contribution Award for China Listed Companies and the 2021 Evergreen Award for Innovative Pharmaceutical Company of the Year.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1998
- Headquarters
- Dongcheng District, China
- Employees
- 489
- Open positions
- 2
- Dealroom signal
- 36.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Diabetes, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Investment activity
- 1 company, latest Nov 2021
- Capital deployed
- $69M
- Preferred round
- SERIES D
- Links
- Website
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Jun 2020 | $360M | $5B | Undisclosed | — |
| GROWTH EQUITY VC✓Equity / VC | Nov 2014 | — | $1.5B | Qiming Venture Partners · Goldman Sachs · Hillhouse Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Gan & Lee Pharmaceutical is 3.8K monthly website visits, up 35.7% over the last three months. Gan & Lee Pharmaceutical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Gan & Lee Pharmaceutical in the Dongcheng District ecosystem
The Gan & Lee Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
Peking University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gan & Lee Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gan & Lee Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











